<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880265</url>
  </required_header>
  <id_info>
    <org_study_id>2021P000356</org_study_id>
    <nct_id>NCT04880265</nct_id>
  </id_info>
  <brief_title>Assessing the Burden of Perioperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery</brief_title>
  <official_title>Assessing the Burden of Perioperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and Significance:&#xD;
&#xD;
      In the United States approximately 220,000 patients undergo cardiac surgery per annum. Among&#xD;
      potential complications, the incidence of atrial fibrillation (AF) is estimated at 30 - 60 %,&#xD;
      and therefore presents the most common adverse event after cardiac surgery. Multiple&#xD;
      complications may be associated with AF: Patients are usually subject to an increased&#xD;
      length-of-stay in the intensive care unit and in the hospital. Furthermore, the risk for&#xD;
      stroke and development of long-term AF is elevated, while further anticoagulation is required&#xD;
      putting the patient at risk for bleeding. On average, an additional $10,000 - $20,000 is&#xD;
      spent for each patient with AF. However, the exact burden of postoperative AF still remains&#xD;
      unknown.&#xD;
&#xD;
      Specific Aims of Research Project:&#xD;
&#xD;
        1. To collect data from an electrocardiogram (EKG) monitoring patch, we aim to accurately&#xD;
           determine the prevalence of atrial fibrillation in patients undergoing cardiac surgery&#xD;
           at our center.&#xD;
&#xD;
        2. To collect data on epidemiological characteristics to investigate risk factors for&#xD;
           developing perioperative atrial fibrillation in patients undergoing cardiac surgery.&#xD;
           This will allow us to create robust risk prediction models.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2021</start_date>
  <completion_date type="Anticipated">May 2030</completion_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial Fibrillation</measure>
    <time_frame>Up to 30 days after discharge from the hospital</time_frame>
    <description>Atrial Fibrillation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other arrhythmias</measure>
    <time_frame>Up to 30 days after discharge from the hospital</time_frame>
    <description>Other arrhythmias</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Patients undergoing cardiac surgery</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BraveHeart wearable life sensors</intervention_name>
    <description>Collection of EKG data</description>
    <arm_group_label>Patients undergoing cardiac surgery</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients undergoing cardiac surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elective open heart surgery&#xD;
&#xD;
          -  Age &gt; 20 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate (patient or health care proxy)&#xD;
&#xD;
          -  Participation in other pharmacological trials&#xD;
&#xD;
          -  Lack of data or poor data quality which cannot be analyzed for any heart rhythm in 80%&#xD;
             of the postoperative study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jochen D Muehlschlegel, MD MMSc MBA</last_name>
    <phone>6175258156</phone>
    <email>jmuehlschlegel@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jakob Wollborn, MD</last_name>
    <phone>6177327330</phone>
    <email>jwollborn@bwh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen D Muehlschlegel, MD, MMSc</last_name>
      <phone>617-732-7330</phone>
      <email>jmuehlschlegel@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jochen D Muehlschlegel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jochen Daniel Muehlschlegel, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Wearable Device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

